{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:23:47Z","timestamp":1790299427931,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":177,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2024.100830","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T19:50:31Z","timestamp":1719604231000},"page":"100830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"Kanako","family":"Sakaeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kurose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanae","family":"Sugasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Irino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Atarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Yanagida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Oga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2024.100830_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer. J. Clin"},{"key":"10.1016\/j.ctarc.2024.100830_bib0002","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2024.100830_bib0003","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0004","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update","volume":"38","author":"Hanna","year":"2020","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0005","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2021.03.017","article-title":"Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors","volume":"16","author":"Memmott","year":"2021","journal-title":"J. Thorac. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0006","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0007","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1158\/1078-0432.CCR-21-1355","article-title":"Intratumor heterogeneity and antitumor immunity shape one another bidirectionally","volume":"28","author":"Wolf","year":"2022","journal-title":"Clin. Cancer. Res"},{"key":"10.1016\/j.ctarc.2024.100830_bib0008","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jtho.2021.03.028","article-title":"Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer","volume":"16","author":"Hwang","year":"2021","journal-title":"J. Thorac. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0009","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jtho.2020.12.026","article-title":"The international association for the study of lung cancer global survey on programmed death-ligand 1 testing for NSCLC","volume":"16","author":"Mino-Kenudson","year":"2021","journal-title":"J. Thorac. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0010","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","article-title":"Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities","volume":"22","author":"Laumont","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2024.100830_bib0011","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: an intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ctarc.2024.100830_bib0012","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","article-title":"Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer","volume":"40","author":"Patil","year":"2022","journal-title":"Cancer. Cell"},{"key":"10.1016\/j.ctarc.2024.100830_bib0013","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jtho.2019.08.008","article-title":"Serum antibody against NY-ESO-1 and XAGE1 antigens potentially predicts clinical responses to anti-programmed cell death-1 therapy in NSCLC","volume":"14","author":"Ohue","year":"2019","journal-title":"J. Thorac. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0014","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/j.1349-7006.2009.01303.x","article-title":"Cancer\/testis (ct) antigens: potential targets for immunotherapy","volume":"100","author":"Caballero","year":"2009","journal-title":"Cancer. Sci"},{"key":"10.1016\/j.ctarc.2024.100830_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","article-title":"NY-ESO-1: review of an immunogenic tumor antigen","volume":"95","author":"Gnjatic","year":"2006","journal-title":"Adv. Cancer. Res."},{"key":"10.1016\/j.ctarc.2024.100830_bib0016","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2326-6066.CIR-15-0266","article-title":"Survival of lung adenocarcinoma patients predicted from expression of PD-L1, galectin-9, and XAGE1 (GAGED2a) on tumor cells and tumor-infiltrating T cells","volume":"4","author":"Ohue","year":"2016","journal-title":"Cancer. Immunol. Res."},{"key":"10.1016\/j.ctarc.2024.100830_bib0017","doi-asserted-by":"crossref","first-page":"E649","DOI":"10.1002\/ijc.27359","article-title":"Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1B (GAGED2a) in non-small cell lung cancer patients","volume":"131","author":"Ohue","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2024.100830_bib0018","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cca.2021.04.008","article-title":"A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer","volume":"519","author":"Sakai","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ctarc.2024.100830_bib0019","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/ijc.22583","article-title":"Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients","volume":"120","author":"Kawabata","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2024.100830_bib0020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow TransPlant"},{"key":"10.1016\/j.ctarc.2024.100830_bib0021","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0022","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0023","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2024.100830_bib0024","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13195-022-01029-0","article-title":"Fully automated and highly specific plasma beta-amyloid immunoassays predict beta-amyloid status defined by amyloid positron emission tomography with high accuracy","volume":"14","author":"Yamashita","year":"2022","journal-title":"Alzheimers. Res. Ther"},{"key":"10.1016\/j.ctarc.2024.100830_bib0026","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1038\/s41598-021-84387-3","article-title":"A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies","volume":"11","author":"Noda","year":"2021","journal-title":"Sci. Rep"},{"key":"10.1016\/j.ctarc.2024.100830_bib0027","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0028","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMa. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0029","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/EDBK_280795","article-title":"Checkpoint blockade in lung cancer with driver mutation: choose the road wisely","volume":"40","author":"Calles","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ctarc.2024.100830_bib0031","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41568-020-00322-0","article-title":"Antitumour immunity regulated by aberrant ERBB family signalling","volume":"21","author":"Kumagai","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2024.100830_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","author":"Mok","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2024.100830_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9000","article-title":"Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study","volume":"41","author":"Yang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2024.100830_bib0034","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","author":"Park","year":"2023","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.ctarc.2024.100830_bib0035","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity."},{"key":"10.1016\/j.ctarc.2024.100830_bib0036","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/OP.23.00014","article-title":"Perioperative therapy for resectable non-small-cell lung cancer: weighing options for the present and future","volume":"19","author":"Uprety","year":"2023","journal-title":"JCo. Oncol. Pract."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422400042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422400042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:19:22Z","timestamp":1728292762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422400042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":36,"alternative-id":["S246829422400042X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100830","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100830"}}